April 30th 2024
A pivotal phase 2 study evaluating glecirasib for the treatment of KRAS G12C-mutated advanced non-small cell lung cancer met its primary end point with an encouraging overall response rate.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Bintrafusp Alfa Shows Similar Efficacy to Pembrolizumab in PD-L1-High/Advanced NSCLC
September 1st 2023No significant difference in efficacy outcomes were shown with bintrafusp alfa vs pembrolizumab in patients with PD-L1-high, advanced non–small cell lung cancer. However, further investigation may offer more information about the benefit of this drug class.
Read More
TROPION-Lung01 Trial of Datopotamab Deruxtecan Meets PFS End Point in NSCLC
July 10th 2023Progression-free survival data from the phase 3 TROPION-Lung01 trial showed that datopotamab deruxtecan as treatment of metastatic non–small cell lung cancer crossed the threshold for statistical significance.
Read More
Pembrolizumab Maintains Efficacy After 5 Years in First-Line, PD-L1+, Advanced NSCLC
July 1st 2023Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer.
Read More
Rezivertinib Generates Promising CNS Efficacy in NSCLC With an EGFR T790M Mutation
June 19th 2023Individual data from 2 studies evaluating rezivertinib in patients with advanced non–small cell lung cancer harboring an EGFR T790M mutation and CNS metastases displayed encouraging efficacy and safety findings.
Read More
Real-World Data Shows Significant Increase of Biomarker Testing in Past Decade for NSCLC
May 8th 2023Looking at real-world data, researchers identified a large increase of biomarker testing for patients with early-stage non–small cell lung cancer, which indicates a continuing trend toward personalized treatment.
Read More
Langer Assesses Several Targeted Treatment Options in the Non–Small Cell Lung Cancer Landscape
April 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Corey J. Langer, MD, discussed the EMPOWER Lung-3 and POSEIDON trials of immunotherapy options in patients with non–small cell lung cancer.
Read More
Updated Results Show Promise for IBI351 Monotherapy in KRAS G12C-Mutated Advanced NSCLC
April 17th 2023Updated results from the phase 1 study of the bioavailable KRAS G12C inhibitor IBI351 showed that monotherapy was tolerable with promising activity in patients with advanced non–small cell lung cancer whose tumor harbored the KRAS G12C mutation.
Read More
Taletrectinib Sustains Positive Efficacy and Safety in ROS1-Positive NSCLC
April 7th 2023With 1.5 years of follow-up, the confirmed objective response rate was 92.5% among patients who were ROS1 tyrosine kinase inhibitor-naïve and 52.6% in crizotinib-pretreated patients in the phase 2 TRUST-I trial.
Read More
FDA Accepts sNDAs for Encorafenib and Binimetinib for BRAF V600-Mutated NSCLC
April 4th 2023Results from the phase 2 PHAROS trial of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non–small cell lung cancer has led the FDA to accept supplemental new drug applications for the agents. Further data will be presented at an upcoming medical meeting.
Read More
Amivantamab Shows Long-term Efficacy/Safety in Post-Platinum EGFR Exon 20 Insertion+ NSCLC
April 2nd 2023Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.
Read More
Clinicians Must Address Unusual AEs of BRAF/MEK Inhibition for BRAF-Mutated NSCLC
March 17th 2023A case report published in The Journal of the National Comprehensive Cancer Center highlights the importance of being mindful of unusual adverse events associated with BRAF/MEK inhibition for patients with BRAF-mutated non–small cell lung cancer.
Read More